A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

Osteoporosis Clinical Trial

Official title:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05067335
• Other study ID #: OP0002
• Status: Completed
• Phase: Phase 3
• Start date: October 21, 2021
• Est. completion date: November 9, 2023

Study information

• Verified date: November 2023
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in postmenopausal Chinese women with osteoporosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 564
• Est. completion date: November 9, 2023
• Est. primary completion date: November 9, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 55 Years to 90 Years

Eligibility

Inclusion Criteria:

• Subject is considered reliable and capable of adhering to the protocol, visit schedule, and medication intake according to the judgment of the investigator
• Subject is an ambulatory postmenopausal Chinese women, 55 to 90 years of age (inclusive) at the time of Screening. Postmenopause is defined as no spontaneous vaginal bleeding or spotting for 12 or more consecutive months prior to Screening
• Subject has a bone mineral density (BMD) T-score =-2.50 at the lumbar spine, total hip, or femoral neck, as assessed by the central imaging vendor at the time of Screening based on DXA scans, and using data for Caucasian women from the National Health and Nutritional Examination Survey (NHANES, 1998)
• Subject must have at least 1 of following independent risk factors for fracture:
• History of fragility fracture (except hip fracture, a severe vertebral fracture or more than 2 moderate vertebral fractures)
• Parental history of hip fracture
• Low body weight (body mass index =19kg/m2)
• Elderly (age = 65 years)
• Current smoker
• Subject has at least 2 vertebrae in the L1 to L4 region and at least 1 hip that are evaluable by dual-energy x-ray absorptiometry (DXA), as assessed by the central imaging vendor

Exclusion Criteria:

• Subject has a BMD T-score of =-3.50 at the total hip or femoral neck, as assessed by the central imaging vendor at the time of Screening based on DXA scans, and using data for Caucasian women from NHANES 1998
• Subject has a known history of hip fracture
• Subject has any severe (SQ3) or more than 2 moderate (SQ2) vertebral fractures, as assessed by the central imaging vendor based on the lateral spine x-ray at Screening
• Subject has a history of myocardial infarction (MI)
• Subject has a history of stroke
• Subject has a vitamin D insufficiency, defined as 25 (OH) vitamin D levels <20 ng/mL, as assessed by the central laboratory at Screening. Vitamin D repletion will be permitted and the subject may be retested once within the Screening Period
• Subject has used oral bisphosphonates:
• Any doses received within 3 months prior to randomization
• More than 1 month of cumulative use between 3 and 12 months prior to randomization
• More than 3 years of cumulative use, unless the last dose was received =5 years prior to randomization
• Subject has used intravenous (iv) bisphosphonates:
• zoledronic acid
• Any doses received within 3 years prior to randomization
• More than 1 dose received within 5 years prior to randomization
• iv ibandronate, iv pamidronate, or iv alendronate (ALN)
• Any doses received within 12 months prior to randomization
• More than 3 years of cumulative use, unless the last dose was received =5 years prior to randomization
• Subject has used denosumab or any cathepsin K inhibitor:

? Any doses received within 18 months prior to randomization

• Subject has used tibolone, cinacalcet, or calcitonin:
• Any doses received within 3 months prior to randomization
• Subject has used teriparatide (TPTD) or any parathyroid hormone (PTH) derivative:
• Any doses received within 3 months prior to randomization
• More than 1 month of cumulative use between 3 and 12 months prior to randomization
• Subject has used systemic oral or transdermal estrogen or selective estrogen receptor modulators (SERMs): ? More than 1 month of cumulative use within 6 months prior to randomization
• Subject has used strontium ranelate or fluoride:

? More than 1 month of cumulative use within 5 years prior to randomization

• Subject has used hormonal ablation therapy:

? More than 1 month of cumulative use within 6 months prior to randomization

• Subject has used systemic glucocorticosteroids:

? =5mg prednisone equivalent per day for more than 14 days within 3 months prior to randomization

• Subject has a history of osteonecrosis of the jaw (ONJ) or atypical femoral fracture (AFF)
• Subject has evidence of any of the following:

1. Current, uncontrolled hyper- or hypothyroidism. Uncontrolled hyperthyroidism is defined as thyroid-stimulating hormone (TSH) and thyroxine (T4) outside of the normal range. Uncontrolled hypothyroidism is defined as TSH >10

2. Current, uncontrolled hyperparathyroidism or history of hypoparathyroidism. Uncontrolled hyperparathyroidism is defined as PTH outside the normal range in subjects with concurrent hypercalcemia or PTH values >20 % above upper limit of normal (ULN) in normocalcemic subjects

3. Current hypercalcemia or hypocalcemia, defined as albumin-adjusted serum calcium outside the normal range, as assessed by the central laboratory at the time of Screening. Albumin-adjusted serum calcium levels may be retested once in case of an elevated albumin-adjusted serum calcium level within 1.1xULN of the laboratory's reference ranges

4. Subject has =3xULN of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total bilirubin (=1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin <35 %)

Related Conditions & MeSH terms

• Osteoporosis

Intervention

Drug:
• Romosozumab
Subjects will receive romosozumab in a specified sequence during the treatment Period.
• Placebo
Subjects will receive Placebo in a specified sequence during the treatment Period.

Locations

Country	Name	City	State
China	Op0002 20040	Beijing
China	Op0002 20115	Beijing
China	Op0002 20125	Beijing
China	Op0002 20127	Beijing
China	Op0002 20128	Beijing
China	Op0002 20130	Beijing
China	Op0002 20131	Beijing
China	Op0002 20157	Beijing
China	Op0002 20021	Chengdu
China	Op0002 20133	Chengdu
China	Op0002 20137	Chengdu
China	Op0002 20205	Foshan
China	Op0002 20117	Guangzhou
China	Op0002 20124	Guangzhou
China	Op0002 20209	Nanchang
China	Op0002 20135	Nanjing
China	Op0002 20202	Pingxiang
China	Op0002 20199	Rui'an
China	Op0002 20116	Shanghai
China	Op0002 20118	Shanghai
China	Op0002 20121	Shanghai
China	Op0002 20123	Shanghai
China	Op0002 20129	Shanghai
China	Op0002 20119	Suzhou
China	Op0002 20204	Suzhou
China	Op0002 20122	Tianjin
China	Op0002 20136	Tianjin
China	Op0002 20120	Wuhan
China	Op0002 20134	Yueyang
China	Op0002 20132	Zhengzhou

Sponsors (1)

Lead Sponsor	Collaborator
UCB Biopharma SRL

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change from Baseline in bone mineral density (BMD) at the lumbar spine	Percent change from Baseline in bone mineral density (BMD) at the lumbar spine at the end of the Double-Blind, Placebo-Controlled Period (Month 6) as assessed by dual-energy x-ray absorptiometry (DXA) by treatment group.	From Baseline to the end of the Double-Blind, Placebo-Controlled Period (Month 6)
Primary	Incidence of treatment-emergent adverse events (TEAEs)	An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.	From Baseline to the end of the Double-Blind, Placebo-Controlled Period (Month 6)
Primary	Incidence of treatment-emergent adverse events (TEAEs) during the Open-Label Treatment Period	An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.	From the Open-Label Treatment Period up to Month 15
Secondary	Percent change from Baseline in bone mineral density (BMD) at the total hip	Percent change from Baseline in bone mineral density (BMD) at the total hip at the end of the Double-Blind, Placebo-Controlled Period (Month 6) as assessed by dual-energy x-ray absorptiometry (DXA) by treatment group.	From Baseline to the end of the Double-Blind, Placebo-Controlled Period (Month 6)
Secondary	Percent change from Baseline in bone mineral density (BMD) at the femoral neck	Percent changes from Baseline in bone mineral density (BMD) at the femoral neck at the end of the Double-Blind, Placebo-Controlled Period (Month 6) as assessed by dual-energy x-ray absorptiometry (DXA) by treatment group.	From Baseline to the end of the Double-Blind, Placebo-Controlled Period (Month 6)
Secondary	Percent change from Baseline in bone mineral density (BMD) at the lumbar spine at the end of the Open-Label Treatment Period	Percent change from Baseline in bone mineral density (BMD) at the lumbar spine, at the end of OLE Period (Month 12) as assessed by dual-energy x-ray absorptiometry (DXA) in subjects who are continuing with 6 months of romosozumab treatment after initially being randomized to 6 months of romosozumab treatment in the Double-Blind, Placebo-Controlled Period (for a total of 12 months of romosozumab treatment).	From Baseline to the end of the Open-Label Extension (OLE) Period (Month 12)
Secondary	Percent change from Baseline in bone mineral density (BMD) at the total hip at the end of the Open-Label Treatment Period	Percent change from Baseline in bone mineral density (BMD) at the total hip, at the end of OLE Period (Month 12) as assessed by dual-energy x-ray absorptiometry (DXA) in subjects who are continuing with 6 months of romosozumab treatment after initially being randomized to 6 months of romosozumab treatment in the Double-Blind, Placebo-Controlled Period (for a total of 12 months of romosozumab treatment).	From Baseline to the end of the Open-Label Extension (OLE) Period (Month 12)
Secondary	Percent change from Baseline in bone mineral density (BMD) at the femoral neck at the end of the Open-Label Treatment Period	Percent change from Baseline in bone mineral density (BMD) at the femoral neck, at the end of OLE Period (Month 12) as assessed by dual-energy x-ray absorptiometry (DXA) in subjects who are continuing with 6 months of romosozumab treatment after initially being randomized to 6 months of romosozumab treatment in the Double-Blind, Placebo-Controlled Period (for a total of 12 months of romosozumab treatment).	From Baseline to the end of the Open-Label Extension (OLE) Period (Month 12)